B7-2/GM-CSF cancer gene therapy - Radient/Jaiva/NuVaxAlternative Names: CIT; Combination Immunogene Therapy
Latest Information Update: 12 Dec 2010
At a glance
- Originator Radient Pharmaceuticals Corporation
- Class Cancer vaccines; Cytokine genes; Gene therapies
- Mechanism of Action T lymphocyte stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase I Cancer